59127-99-0

Basic information

• Product Name: IMidazo[1,2-a]pyridine-2-acetic acid, 6-Methyl-, ethyl ester
• Synonyms: IMidazo[1,2-a]pyridine-2-acetic acid, 6-Methyl-, ethyl ester;Ethyl (6-methylimidazo[1,2-a]pyridin-2-yl)-acetate;ethyl 2-(6-methylH-imidazo[1,2-a]pyridin-2-yl)acetate
• CAS NO: 59127-99-0
• Molecular Formula: C12H14N2O2
• Molecular Weight: 218.25176
• Mol File: 59127-99-0.mol

Chemical Properties

• Boiling Point: 141-145 °C(Press: 1 Torr)
• Appearance: /
• Density: 1.17g/cm³
• Refractive Index: 1.575
• PKA: 6.76±0.50(Predicted)
• CAS DataBase Reference: IMidazo[1,2-a]pyridine-2-acetic acid, 6-Methyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine-2-acetic acid, 6-Methyl-, ethyl ester(59127-99-0)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine-2-acetic acid, 6-Methyl-, ethyl ester(59127-99-0)

Safety Data

• Hazardous Substances Data: 59127-99-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H14N2O2/c1-3-16-12(15)6-10-8-14-7-9(2)4-5-11(14)13-10/h4-5,7-8H,3,6H2,1-2H3

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 638-07-3 ethyl (2-chloroaceto)acetate 

Relevant articles and documents

METTL3 INHIBITORY COMPOUNDS

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z5 (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity 10 is implicated.

Compounds for treating spinal muscular atrophy

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY

Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.